Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735060 | 0.85 | SMN1; SMN2 (0.38) | ALDH1A1LMNARAB9AKMT2AGAA | |
| SCHEMBL7254072 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MAPTKMT2AGAAMAPK1 | |
| SCHEMBL6730542 | 0.84 | CYP3A4 (0.35) | NPSR1CYP3A4CYP2C19 | |
| SCHEMBL20564117 | 0.80 | TSHR (0.47) | TSHRALDH1A1MAPTLMNARAB9A | |
| SCHEMBL4816648 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KMT2ANPSR1MEN1CYP3A4 | |
| SCHEMBL6782433 | 0.78 | TSHR (0.42) | TSHRALDH1A1MAPTLMNARAB9A | |
| SCHEMBL6639985 | 0.78 | CYP2C19 (0.31) | ALDH1A1CYP2C19 | |
| SCHEMBL24242177 | 0.77 | TSHR (0.41) | TSHRALDH1A1MAPTLMNARAB9A | |
| SCHEMBL7301501 | 0.77 | TSHR (0.41) | TSHRALDH1A1MAPTLMNARAB9A | |
| SCHEMBL7302799 | 0.77 | TSHR (0.41) | TSHRALDH1A1MAPTLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706719-B1 | COMPOUNDS WHICH HAVE THE PROPERTY OF INHIBITING THE ACTION OF METALLOPROTEINASES INVOLVED IN CONNECTIVE TISSUE BREAKDOWN | DARWIN DISCOVERY, LTD. (GB) | 2004-03-16 | — | — | US | disclosed |
| US-6686348-B2 | N-HYDROXY-6-((2-(4-PYRIDYL)-1-BENZOFURAN-5-YL)SULPHONYL)-4,5,6,7 -TETRAHYDRO(2,3-C)-PYRIDINE-5-CARBOXAMIDE FOR EXAMPLE; TREATING RHEUMATIC DISEASES, CANCER | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| EP-1030836-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20020137744-A1 | Metalloprotease inhibitors | LES LABORATOIRES SERVIER (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-1129086-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| US-6187924-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TUMOR NECROSIS FACTOR-ALPHA-MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
| EP-1030836-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000029401-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999024399-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137744-A1 | Metalloprotease inhibitors | MMP9, MMP3, MMP2 | TSHR 1605/4885ALDH1A1 201/4885MAPT 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.